WHO ICTRP trial
Efficacy of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular…
JPRN-UMIN000042750 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000042750 |
|---|---|
| Public title | Efficacy of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma |
| Scientific title | Efficacy of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma - Efficacy of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma |
| Primary sponsor | Gifu university first Dept of internalmedicine |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Observational |
| Phase | Not selected |
| Countries | Japan |
| Conditions | Hepatocellular Carcinoma |
| Registration date | Dec 21, 2020 |
| Target size | 300 |
| Secondary IDs | 2020-190 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: